92 related articles for article (PubMed ID: 34926138)
1. 2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies.
Hariyono P; Dwiastuti R; Yusuf M; Salin NH; Hariono M
Results Chem; 2022 Jan; 4():100263. PubMed ID: 34926138
[TBL] [Abstract][Full Text] [Related]
2. COVID-19: In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2.
Oubahmane M; Hdoufane I; Bjij I; Jerves C; Villemin D; Cherqaoui D
J Mol Struct; 2021 Nov; 1244():130897. PubMed ID: 34149065
[TBL] [Abstract][Full Text] [Related]
3. In Silico Identification of New Anti-SARS-CoV-2 Main Protease (M
Onyango H; Odhiambo P; Angwenyi D; Okoth P
J Trop Med; 2022; 2022():3697498. PubMed ID: 36263438
[TBL] [Abstract][Full Text] [Related]
4.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
5. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
6. Natural inhibitors of SARS-CoV-2 main protease: structure based pharmacophore modeling, molecular docking and molecular dynamic simulation studies.
Halimi M; Bararpour P
J Mol Model; 2022 Aug; 28(9):279. PubMed ID: 36031629
[TBL] [Abstract][Full Text] [Related]
7. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
8. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
9. Discovery of C-12 dithiocarbamate andrographolide analogues as inhibitors of SARS-CoV-2 main protease:
Nutho B; Wilasluck P; Deetanya P; Wangkanont K; Arsakhant P; Saeeng R; Rungrotmongkol T
Comput Struct Biotechnol J; 2022; 20():2784-2797. PubMed ID: 35677603
[TBL] [Abstract][Full Text] [Related]
10. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
11. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
12. Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M
Franco LS; Maia RC; Barreiro EJ
RSC Med Chem; 2021 Jan; 12(1):110-119. PubMed ID: 34046603
[TBL] [Abstract][Full Text] [Related]
13. Integrated computational approach towards repurposing of antimalarial drug against SARS-CoV-2 main protease.
Gogoi N; Chowdhury P; Goswami AK; Das A; Chetia D; Gogoi B
Struct Chem; 2022; 33(5):1409-1422. PubMed ID: 35669793
[TBL] [Abstract][Full Text] [Related]
14. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
[TBL] [Abstract][Full Text] [Related]
15. In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from
Mengist HM; Khalid Z; Adane F
Adv Appl Bioinform Chem; 2023; 16():1-13. PubMed ID: 36699952
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
[TBL] [Abstract][Full Text] [Related]
17. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
18. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
19.
Ram TS; Munikumar M; Raju VN; Devaraj P; Boiroju NK; Hemalatha R; Prasad PVV; Gundeti M; Sisodia BS; Pawar S; Prasad GP; Chincholikar M; Goel S; Mangal A; Gaidhani S; Srikanth N; Dhiman KS
J Ayurveda Integr Med; 2022; 13(1):100413. PubMed ID: 33654345
[TBL] [Abstract][Full Text] [Related]
20. In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library.
Shahhamzehei N; Abdelfatah S; Efferth T
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
